KEGG   ORTHOLOGY: K06621Help
Entry
K06621                      KO                                     

Name
CDKN2A, P16, INK4A
Definition
cyclin-dependent kinase inhibitor 2A
Pathway
ko01522  Endocrine resistance
ko01524  Platinum drug resistance
ko04110  Cell cycle
ko04115  p53 signaling pathway
ko04218  Cellular senescence
ko04934  Cushing's syndrome
ko05166  HTLV-I infection
ko05200  Pathways in cancer
ko05203  Viral carcinogenesis
ko05206  MicroRNAs in cancer
ko05212  Pancreatic cancer
ko05214  Glioma
ko05218  Melanoma
ko05219  Bladder cancer
ko05220  Chronic myeloid leukemia
ko05223  Non-small cell lung cancer
ko05225  Hepatocellular carcinoma
Disease
H00004  Chronic myeloid leukemia (CML)
H00008  Burkitt lymphoma
H00009  Adult T-cell leukemia
H00014  Non-small cell lung cancer
H00015  Malignant pleural mesothelioma
H00016  Oral cancer
H00017  Esophageal cancer
H00019  Pancreatic cancer
H00022  Bladder cancer
H00025  Penile cancer
H00036  Osteosarcoma
H00038  Melanoma
H00040  Squamous cell carcinoma
H00042  Glioma
H00046  Cholangiocarcinoma
H00047  Gallbladder cancer
H00048  Hepatocellular carcinoma
H00054  Nasopharyngeal cancer
H00055  Laryngeal cancer
H00409  Type II diabetes mellitus
H01463  Mycosis fungoides
H01464  Mantle cell lymphoma
H01508  Salivary gland cancer
H01509  Tonsillar cancer
H01513  Retinoblastoma
H01556  Meningioma
Brite
KEGG Orthology (KO) [BR:ko00001]
 Cellular Processes
  Cell growth and death
   04110 Cell cycle
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   04115 p53 signaling pathway
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   04218 Cellular senescence
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
 Human Diseases
  Cancers
   05200 Pathways in cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05206 MicroRNAs in cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05203 Viral carcinogenesis
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05212 Pancreatic cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05225 Hepatocellular carcinoma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05214 Glioma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05220 Chronic myeloid leukemia
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05218 Melanoma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05219 Bladder cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05223 Non-small cell lung cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  Endocrine and metabolic diseases
   04934 Cushing's syndrome
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  Infectious diseases
   05166 HTLV-I infection
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  Drug resistance
   01524 Platinum drug resistance
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   01522 Endocrine resistance
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
BRITE hierarchy
Other DBs
GO: 0004861
Genes
HSA: 1029(CDKN2A)
PTR: 465021(CDKN2A)
PPS: 100975637(CDKN2A)
GGO: 101145463(CDKN2A)
PON: 100461015
NLE: 100586796(CDKN2A)
MCC: 709988
MCF: 102135474(CDKN2A)
RRO: 104654275(CDKN2A)
RBB: 108537054(CDKN2A)
CJC: 100394189(CDKN2A)
SBQ: 101038444
MMU: 12578(Cdkn2a)
RNO: 25163(Cdkn2a)
CGE: 100764983(Cdkn2a)
NGI: 103730663
CCAN: 109701107
OCU: 100340625(CDKN2A)
CFA: 100271861(CDKN2A)
AML: 100472171(CDKN2A)
FCA: 101089220(CDKN2A)
AJU: 106986386
BTA: 616369(CDKN2A)
BOM: 102284461(CDKN2A)
BIU: 109562627
PHD: 102315805(CDKN2A)
CDK: 105092872
BACU: 103012968(CDKN2A)
LVE: 103072667(CDKN2A)
OOR: 101276268(CDKN2A)
ECB: 100146270
EAI: 106824796
HAI: 109374675
RSS: 109436478
LAV: 104845647
TMU: 101345867
OAA: 100083932
 » show all
TaxonomyKoalaUniProt
Reference
PMID:8259215
  Authors
Serrano M, Hannon GJ, Beach D
  Title
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
  Journal
Nature 366:704-7 (1993)
DOI:10.1038/366704a0
  Sequence
[hsa:1029]
Reference
PMID:9724636
  Authors
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G
  Title
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
  Journal
EMBO J 17:5001-14 (1998)
DOI:10.1093/emboj/17.17.5001
  Sequence
[hsa:1029]

DBGET integrated database retrieval system